Comar to Unveil AccuCup, New Company Branding at Pharmapack North America

Comar LLC will be unveiling its latest products and new branding at Pharmapack North America in New York on June 9-10 following its merger with Convergence Packaging last October. It will be located at booth 4105.

Aphena Pharma Solutions Acquires 14 OTC Private-Label Products

Aphena Pharma Solutions Inc., a contract packager, repackager, and manufacturer for the pharmaceutical, OTC, dietary supplements, animal health, health and beauty, consumer health, and medical device markets, has acquired 14 OTC products from G&W Laboratories.

The company reports in a press release that the acquisition is part of its strategy "to expand its existing and future customers' access to the growing private-label marketplace by purchasing both small- and large-scale private-label offerings."

Viosan Health Promotes OTC Probiotic Supplement to Fight Flu

The company claims the dietary supplement helps maintain the presence of “good” bacteria during antibiotic influenza treatment.

As the entire Western Hemisphere approaches winter, flu season comes along with it. In the United States, National Influenza Vaccination Week (December 2-8, 2012) promotes awareness of getting flu shots and vaccines. It is important to build up our immune systems during this time. Antibiotics aid the immune system by attacking and killing infectious strains present in the human body. However, antibiotic treatments are engineered to attack contagions across a broad spectrum, thus killing all kinds of bacteria, whether they are beneficial to the body or not.

No votes yet

Perrigo to Launch Mini Nicotine Lozenges

The drug firm has received the go-ahead from the FDA to market the OTC smoking-cessation product.

The Perrigo Company today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) to market over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).

Your rating: None Average: 5 (1 vote)
Syndicate content